Post calls conspiracy allegations about Snoop Dogg's cereal 'completely false'
https://www.startribune.com/post-snoop-dogg-cereal-broadus-foods-master-p-minnesota-lawsuit-walmart-rapper/600356014/
Apr 03, 2024 - The rapper's company, Broadus Foods, is suing the Minnesota cereal maker and Walmart after poor sales of Snoop Cereal.
0
Sandstorm Gold (SAND) Posts Y/Y Preliminary Q1 Revenue Decline
https://www.zacks.com/stock/news/2252778/sandstorm-gold-sand-posts-y-y-preliminary-q1-revenue-decline?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2252778
Apr 09, 2024 - Sandstorm Gold's (SAND) preliminary revenues fall 2.7% year over year, while cash operating margins improve 7.8% in the first quarter.
0
Delta Air Lines posts a narrow Q1 profit and says travel demand remains strong despite flight scares
https://www.startribune.com/delta-air-lines-posts-a-narrow-q1-profit-and-says-travel-demand-remains-strong-despite-flight-scares/600357697/
Apr 10, 2024 - Delta Air Lines eked out a narrow first-quarter profit and said Wednesday that demand for travel is strong heading into the summer-vacation season, with travelers seemingly unfazed by recent incidents in the industry that ranged from a panel blowing off a jetliner in flight to a tire falling off another plane during takeoff.
0
PACS Group: A Healthy Debut For This Post-Acute Care Provider
https://seekingalpha.com/article/4683413-pacs-group-a-healthy-debut-for-this-acute-care-provider?source=feed_tag_ipo_analysis
Apr 12, 2024 - PACS Group shares rose 10% on the first day of trading after its IPO. Read more to see my recommendation on PACS stock.
0
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2255306/quest-diagnostics-dgx-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2255306
Apr 15, 2024 - Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
0
Clene stock rallies 52% post-market on MS drug data
https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=feed_sector_healthcare
Apr 16, 2024 - Clene (CLNN) stock rallied 52% post-market Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis. Read more here.
0
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2256315/align-technology-algn-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2256315
Apr 16, 2024 - Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
0
Alexandria (ARE) to Post Q1 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2257051/alexandria-are-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257051
Apr 17, 2024 - While Alexandria's (ARE) Q1 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high interest expenses raise concern.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
https://www.zacks.com/stock/news/2257902/danaher-dhr-gears-up-to-post-q1-earnings-is-a-beat-likely?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257902
Apr 18, 2024 - Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
0